Translational Program for Applied Health (TPAH)
Translational Program for Applied Health
In 2003, Genome Canada announced a competition that was focused on the development and application of genome sciences tools to improve the prediction, prevention, and treatment of human disease(s) for individuals and populations (the Applied Genomics and Proteomics Research in Human Health Competition [also known as Applied Human Health]). In 2004, six BC-based projects were approved for funding under this competition, with a three year investment of $44.1 million coming from Genome Canada, Genome BC, and others.
To facilitate the translation of this knowledge into the clinical setting, Genome BC launched the Translational Program for Applied Health (into clinic) (TPAH) as part of its Business Plan, with funding decisions announced March, 2008. The program supports the additional work required to further develop applications resulting from three Applied Human Health Research projects.
The TPAH is a $17 million program with an initial investment of up to $5.6 million from Genome BC. The program supports translational research for up to two years, taking applications to at least, if not beyond, Investigational New Drug (IND) approval/Investigational Testing Authorization (ITA) (or equivalent) stage on their paths towards integration into clinical practice. Projects use existing BC facilities, including platforms, as the TPAH does not assist in the building of new physical capacity. Genome BC funds up to 33% of approved eligible costs of a project, with the balance obtained from other Canadian and international sources such as granting agencies, federal government departments, diagnostic companies, pharmaceutical companies, health authorities, physician groups, etc.
On April 29, 2008 Genome BC announced that three research teams were awarded a combined total of $17 million from Genome BC and other co-funders. These projects include:
